Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Webinar December 2020
20 slides from Noxopharm's conference presentation, December 2020
Slide 1: Noxopharm Limited (ASX:NOX) Webinar Presentation December 2020
Noxopharm Limited (ASX:NOX) WEBINAR PRESENTATION DECEMBER 2020 Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an in
Slide 3: Our single-minded objective
Our single-minded objective ……. ☛ is to prove that Veyonda® ☛ is the answer to unlocking the power of the immune system to fight cancer ☛ allowing the 3 main forms of cancer therapy - immuno-oncology, radiotherapy, chemotherapy - to reach their full potential ☛ identifying Noxopharm as a highly valu
Slide 4: Key R&D achievements in 2020
Key R&D achievements in 2020 ……. DARRT-1 Phase 1b Exciting early study provides median overall 2 Independent evidence of proof- survival data studies confirming of-concept of emerging from that Veyonda works abscopal responses LuPIN study by converVng Bristol-Myers tumours from COLD Squibb commit to
Slide 5: We go into 2021 with a strong cash position
We go into 2021 ……. ☛ with a strong cash posiVon (based on $23M CR and an;cipated R&D Rebate) ☛ providing a full 12-month runway ☛ to meet aim of a[aining proof-of-concept of Veyonda as a major new drug prospect 2020 Noxopharm. All rights reserved.
Slide 6: Veyonda joins the new wave of cancer immuno-oncology therapies
Veyonda joins the new wave of cancer immuno-oncology (I-O) therapies ……. ☛ that aim to restore the body’s immune system to fight cancer ☛ are the acknowledged future of cancer therapy ☛ re-acVvaVng the immune system is readily achieved ☛ the problem is getting the reactivated immune cells back inside
Slide 7: Restoring immune function to tumours
Restoring immune funcVon to tumours T T T T T T T T Veyonda® T T COLD T T T HOT T T T T All healthy tissues Emerging cancer cells With tumour now fully Veyonda block S1P production by cancer cells contain immune cells established, ongoing high (T cells) T S1P levels keep immune With S1P levels down
Slide 8: Employing the unique 'COLD to HOT' Veyonda function
Employing the unique ‘COLD to HOT’ Veyonda funcVon PD-1 IONIC Program therapy Veyonda + checkpoint (PD-1) inhibitors Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy LuPIN Program Radio- Veyonda + (intravenous) radiotherapy therapy Source: Enhancing Immunotherapy: The Race to Make
Slide 9: Employing the unique 'COLD to HOT' Veyonda function
Employing the unique ‘COLD to HOT’ Veyonda funcVon PD-1 IONIC Program therapy Veyonda + checkpoint (PD-1)inhibitors Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy LuPIN Program Radio- Veyonda + (intravenous) radiotherapy therapy Source: Enhancing Immunotherapy: The Race to Make
Slide 10: IONIC Program Veyonda + checkpoint inhibitors
PD-1 IONIC Program therapy Veyonda + checkpoint inhibitors 2019 sales of checkpoint inhibitors US$22 billion Search for Checkpoint Inhibitor partners • Keytruda® Merck • Opdivo ® Bristol-Myers Squibb • Yervoy ® Bristol-Myers Squibb 10-30% response rates in 7 cancers (eg. lung, melanoma, kidney, blad
Slide 11: IONIC-1 Immuno-Oncology With NOX66 In Combination
PD-1 IONIC Program therapy Veyonda + checkpoint inhibitors IONIC-1 Veyonda® + checkpoint Immuno-Oncology With inhibitor NOX66 In Combination Veyonda® + nivolumab (Opdivo®) (Bristol Myers Squibb) Bristol-Myers Squibb (NYSE:BMY) Market cap US$145 billion Pharma ranking 11th 2019 sales US$26 billion A
Slide 12: IONIC-1
PD-1 IONIC Program therapy Veyonda + checkpoint inhibitors IONIC-1 Clinical objecVve #1 Improve low (10-30%) response rates to Opdivo in responsive cancers (eg. lung, melanoma, bladder, kidney) Cohort 1. PaVents recently treated with Opdivo® with mild disease progression Phase I/II study Clinical ob
Slide 13: Direct and Abscopal Response to Radiotherapy
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy Direct and Abscopal Response Transforming a local anti-cancer effect of radiation into a whole-of-body anti-cancer to Radiotherapy effect (abscopal response) Objectives: 1. To convert the abscopal response from a very rare phenomeno
Slide 14: DARRT Program
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy DARRT Program Radiotherapy 4-step DARRT process: Step 1. RadiaVon applied to single tumour Step 2. RadiaVon acVvates immune cells ResoluVon Partial abscopal Complete Step 3. Veyonda augments that local immune of Irradiated tumour re
Slide 15: DARRT-1
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy DARRT-1 Completed 25 men late-stage progressive prostate cancer MetastaVc castraVon-resistant prostate cancer (mCRPC) No remaining standard treatment options Low-dose (palliaVve) radiotherapy (RT) to single sod Vssue tumour Treatmen
Slide 16: Over 50% drop in PSA in evaluable patients
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy In paVents evaluable ader 6 months* ….. Over 50% Over 30% No drop in Abscopal drop in tumour PSA in pain response levels in growth 5/16 in 10/15 in 4/15 10/16 patients paVents paVents patients * 15 paVents eligible for RECIST; 16 fo
Slide 17: DARRT-2 Phase 2 study
Radio- DARRT Program therapy Veyonda + (external beam) radiotherapy DARRT-2 Phase 2 study 150 - 200 patients multi-national Parexel CRO Late-stage cancer. No remaining standard treatment opVons Final planning current. Enrolment to start H1 2021 Prostate cancer, breast cancer, lung cancer Boosted the
Slide 18: LuPIN Program
LuPIN Program Radio- Veyonda + (intravenous) radiotherapy therapy LuPIN program = Veyonda + 177lutetium-PSMA-617 for late-stage prostate cancer 177luteVum-PSMA-617 acquired by NovarVs in 2018 in US$6 billion transacVon St Vincent’s Hospital Sydney tesVng ability of LuPIN therapy to boost modest surv
Slide 19: Objectives
Objectives Over the next 2.5 years, with a modest investment of shareholder funds, to show that …. IONIC Veyonda increases the response rate to nivolumab (Opdivo) (BMS), establishing its potential to boost checkpoint inhibitor drug sales well above current US$22 billion p.a. DARRT Veyonda + radiothe
Slide 20: An I-O therapy to transform the management of cancer
Discover Develop Deliver An I-O therapy to transform the management of cancer www.noxopharm.com Media Enquiries Email: info@noxopharm.com The Capital Network Phone: (+61) 2 9144 2223 Julia Maguire +61 2 8999 3699 h[ps://www.linkedin.com/company/noxopharm-limited julia@thecapitalnetwork.com.au h[ps:/